company background image
CBD

CannasouthNZSE:CBD Stock Report

Market Cap

NZ$53.0m

7D

-2.5%

1Y

-54.1%

Updated

23 Oct, 2021

Data

Company Financials
CBD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CBD Overview

Cannasouth Limited, a biopharmaceutical company, engages in the research, development, production, and supply of cannabis biomass and cannabinoid medicines in New Zealand.

Price History & Performance

Summary of all time highs, changes and price drops for Cannasouth
Historical stock prices
Current Share PriceNZ$0.39
52 Week HighNZ$0.38
52 Week LowNZ$0.85
Beta1.51
1 Month Change-1.27%
3 Month Change-8.24%
1 Year Change-54.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO-2.50%

Recent News & Updates

Feb 17
Read This Before Buying Cannasouth Limited (NZSE:CBD) Shares

Read This Before Buying Cannasouth Limited (NZSE:CBD) Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Shareholder Returns

CBDNZ PharmaceuticalsNZ Market
7D-2.5%0.3%0.4%
1Y-54.1%0.8%2.1%

Return vs Industry: CBD underperformed the NZ Pharmaceuticals industry which returned 0.8% over the past year.

Return vs Market: CBD underperformed the NZ Market which returned 2.1% over the past year.

Price Volatility

Is CBD's price volatile compared to industry and market?
CBD volatility
CBD Beta1.51
Industry Beta1.29
Market Beta1

Stable Share Price: CBD is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CBD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018n/aMark Lucashttps://www.cannasouth.co.nz

Cannasouth Limited, a biopharmaceutical company, engages in the research, development, production, and supply of cannabis biomass and cannabinoid medicines in New Zealand. The company was incorporated in 2018 and is based in Hamilton, New Zealand.

Cannasouth Fundamentals Summary

How do Cannasouth's earnings and revenue compare to its market cap?
CBD fundamental statistics
Market CapNZ$52.98m
Earnings (TTM)-NZ$4.02m
Revenue (TTM)NZ$155.80k

342.1x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBD income statement (TTM)
RevenueNZ$155.80k
Cost of RevenueNZ$0
Gross ProfitNZ$155.80k
ExpensesNZ$4.18m
Earnings-NZ$4.02m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.03
Gross Margin100.00%
Net Profit Margin-2,581.27%
Debt/Equity Ratio0%

How did CBD perform over the long term?

See historical performance and comparison

Valuation

Is Cannasouth undervalued compared to its fair value and its price relative to the market?

4.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CBD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CBD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CBD is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: CBD is unprofitable, so we can't compare its PE Ratio to the NZ market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CBD is overvalued based on its PB Ratio (4.4x) compared to the XO Pharmaceuticals industry average (3.8x).


Future Growth

How is Cannasouth forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

61.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannasouth has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cannasouth performed over the past 5 years?

-43.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CBD is currently unprofitable.

Growing Profit Margin: CBD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CBD's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.1%).


Return on Equity

High ROE: CBD has a negative Return on Equity (-33.24%), as it is currently unprofitable.


Financial Health

How is Cannasouth's financial position?


Financial Position Analysis

Short Term Liabilities: CBD's short term assets (NZ$4.9M) exceed its short term liabilities (NZ$447.5K).

Long Term Liabilities: CBD's short term assets (NZ$4.9M) exceed its long term liabilities (NZ$107.5K).


Debt to Equity History and Analysis

Debt Level: CBD is debt free.

Reducing Debt: CBD had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CBD has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 30.6% each year.


Dividend

What is Cannasouth current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBD's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Mark Lucas

no data

Tenure

NZ$176,523

Compensation

Mr. Mark John Lucas has been Managing Director of Cannasouth Limited since 2021, Executive Director since August 21, 2018 and serves as its Chief Executive Officer. He is an experienced business manager wh...


Leadership Team

Experienced Management: CBD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: CBD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.


Top Shareholders

Company Information

Cannasouth Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cannasouth Limited
  • Ticker: CBD
  • Exchange: NZSE
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NZ$52.980m
  • Shares outstanding: 135.85m
  • Website: https://www.cannasouth.co.nz

Location

  • Cannasouth Limited
  • 240 Victoria Street
  • Level 1
  • Hamilton
  • 3256
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/23 06:01
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.